Cardiac cachexia is a complex and severe condition characterized by the unintended loss of weight, muscle atrophy, and weakness in individuals with chronic heart failure. This condition goes beyond mere weight loss, encompassing a profound depletion of lean body mass and fat stores. It poses a significant challenge in the management of heart failure, often leading to increased morbidity and mortality. The underlying mechanisms of cardiac cachexia involve a complex interplay of inflammation, hormonal imbalance, and metabolic disturbances. Clinically, patients with cardiac cachexia experience a decline in functional capacity and a compromised quality of life. Management strategies typically involve a multidisciplinary approach, focusing on nutritional support, exercise rehabilitation, and addressing the underlying causes of heart failure. Research into the pathophysiology and treatment options for cardiac cachexia is ongoing, aiming to enhance our understanding and improve the prognosis for individuals affected by this debilitating condition.
Title : Pulse field ablation for atrial fibrillation complications: What do we know yet
Narendra Kumar, HeartbeatsZ Academy, United Kingdom
Title : The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF
Thomas Bernd Dschietzig, Relaxera GmbH & Co. KG, Germany
Title : Cancer and cardiovascular diseases: Common pathogenesis mechanisms and risk factors
Mekhman N Mamedov, National Research Center for Preventive Medicine, Russian Federation
Title : Lipoprotein (a): The hidden cardiovascular risk
Syed Raza, Awali Hospital, Bahrain
Title : Innovative mechanisms, consequences and therapeutics for pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Comprehensive surgical revascularization for rapidly worsening ischemic heart failure
Deepak Puri, Max Healthcare, India